Could a Triple-Drug cocktail beat long COVID?
NCT ID NCT07597902
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a combination of three drugs—valacyclovir, celecoxib, and Paxlovid—can reduce Long COVID symptoms in adults. About 150 participants aged 18-65 with diagnosed Long COVID will receive either the drug combo or a placebo. The main goal is to see if the treatment improves self-rated health and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
combination of valacyclovir, celecoxib, and Paxlovid
What this could lead to
If it works, this could point toward a treatment that eases Long COVID symptoms and improves quality of life.
What could go wrong
This is a small, early-phase trial with only 150 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)
New York, New York, 10029, United States
Contact Email: •••••@•••••
Contact